Rare diseases offer insights into autism spectrum disorders. Preliminary laboratory studies suggest new biological targets for intervention.
D000818:Animals; D001321:Autistic Disorder / Q000188:drug therapy / Q000235:genetics*; D004330:Drosophila; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics; D005600:Fragile X Syndrome / Q000188:drug therapy / Q000235:genetics; D018698:Glutamic Acid / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051783:Methyl-CpG-Binding Protein 2 / Q000235:genetics; D051379:Mice; D011494:Protein Kinases / Q000187:drug effects / Q000235:genetics; D015518:Rett Syndrome / Q000188:drug therapy / Q000235:genetics; D020123:Sirolimus / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D014402:Tuberous Sclerosis / Q000188:drug therapy / Q000235:genetics; D000077004:Tuberous Sclerosis Complex 1 Protein; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins / Q000235:genetics
D051860:Fragile X Messenger Ribonucleoprotein 1; D018698:Glutamic Acid; D007166:Immunosuppressive Agents; D051783:Methyl-CpG-Binding Protein 2; D011494:Protein Kinases; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; D000077004:Tuberous Sclerosis Complex 1 Protein; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins; C497683:FMR1 protein, human; C546842:MTOR protein, human; C546843:mTOR protein, mouse